868171-80-6

Basic information

• Product Name: methyl 1-(phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate
• Synonyms: methyl 1-(phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate
• CAS NO: 868171-80-6
• Molecular Weight: 229.235
• Mol File: 868171-80-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl 1-(phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-(phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate(868171-80-6)
• EPA Substance Registry System: methyl 1-(phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate(868171-80-6)

Safety Data

• Hazardous Substances Data: 868171-80-6(Hazardous Substances Data)

Upstream product

• 609-71-2 2-hydroxy-3-carboxypyridine 
• 25991-27-9 methyl 2-oxo-2H-pyrane-3-carboxylate 
• 62-53-3 aniline 
• 393-55-5 2-fluoronicotinic acid 
• 10128-91-3 methyl 2-hydroxynicotinate 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1621689-35-7 C₂₀H₁₅N₃O₃ 
• 1474049-96-1 (Z)-N-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide 
• 868171-81-7 2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid 

Relevant articles and documents

Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor

Bioisosteric replacement of acylureido moiety in 6-acylureido-3- pyrrolylmethylidene-2-oxoindoline derivatives resulted in a series of malonamido derivatives with indolin-2-one scaffold (11-14). Further conformational restrictions of the malonamido moiety led to 2-oxo-1,2-dihydropyridine (21-25) or a 4-oxo-1,4-dihydropyridine derivatives (31-36). 4-Oxo-1,4-dihydropyridine derivatives were more potent Aurora B inhibitors than their 2-oxo-1,2- dihydropyridine counterparts and demonstrated cytotoxicities against A549 and HepG2 cells in the submicromolar range. In A549 cells, 31h decreased phosphorylation of histone H3, triggered polyploidy, induced expression of pro-apoptotic Fas and FasL with subsequent activation of caspase 8, resulting into apoptosis. In a Huh7-xenograft mouse model, 31h demonstrated potent in vivo efficacy with a daily dose of 5 mg/kg.

PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES

A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.

MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF

Provided are compounds that are modulators of C3a receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, the compounds are pyridones. In certain embodiments, provided are methods for treatment or amelioration of diseases associated with modulation of C3a receptor activity.